{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T14:40:18Z","timestamp":1721918418075},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2008,8,20]],"date-time":"2008-08-20T00:00:00Z","timestamp":1219190400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0002980","type":"journal-article","created":{"date-parts":[[2008,8,19]],"date-time":"2008-08-19T21:05:35Z","timestamp":1219179935000},"page":"e2980","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Elevated Peripheral Visfatin Levels in Narcoleptic Patients"],"prefix":"10.1371","volume":"3","author":[{"given":"Norbert","family":"Dahmen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Manderscheid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Helfrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra B.","family":"Musholt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Forst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Pf\u00fctzner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Engel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2008,8,20]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1056\/NEJM199008093230606","article-title":"Narcolepsy.","volume":"323","author":"MS Aldrich","year":"1990","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s004060170057","article-title":"Increased prevalence of obesity in narcoleptic patients and relatives.","volume":"251(2)","author":"N Dahmen","year":"2001","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0140-6736(05)74704-8","article-title":"Increased body-mass index in patients with narcolepsy.","volume":"355(9211)","author":"A Schuld","year":"2000","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0092-8674(00)81973-X","article-title":"Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation.","volume":"98","author":"RM Chemelli","year":"1999","journal-title":"Cell"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0092-8674(00)81965-0","article-title":"The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene.","volume":"98","author":"L Lin","year":"1999","journal-title":"Cell"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(99)05582-8","article-title":"Hypocretin (orexin) deficiency in human narcolepsy.","volume":"355","author":"S Nishino","year":"2000","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/ana.1130","article-title":"Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy.","volume":"50(3)","author":"S Nishino","year":"2001","journal-title":"Ann Neurol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0304-3940(01)02476-4","article-title":"Plasma orexin-A is lower in patients with narcolepsy.","volume":"318(2)","author":"S Higuchi","year":"2002","journal-title":"Neurosci Lett"},{"key":"ref9","first-page":"1012","article-title":"HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients.","volume":"20(11)","author":"E Mignot","year":"1997","journal-title":"Sleep"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1212\/WNL.48.6.1550","article-title":"HLA DR15 (DR2) and DQB1*0602 typing studies in 188 narcoleptic patients with cataplexy.","volume":"48(6)","author":"AE Rogers","year":"1997","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/ana.20339","article-title":"Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset.","volume":"56(6)","author":"Y Dauvilliers","year":"2004","journal-title":"Ann Neurol"},{"key":"ref12","first-page":"461","article-title":"Narcolepsy: a review of evidence for autoimmune diathesis.","volume":"17(6)","author":"JL Black 3rd","year":"2005","journal-title":"Int Rev Psychiatry"},{"key":"ref13","first-page":"361","article-title":"Comparative analysis of patients with narcolepsy-cataplexy, narcolepsy without cataplexy and idiopathic hypersomnia.","volume":"128(10)","author":"JE Mart\u00ednez-Rodr\u00edguez","year":"2007","journal-title":"Med Clin (Barc)"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0889-8529(01)00005-6","article-title":"Sleep, the hypothalamic-pituitary-adrenal axis, and cytokines: multiple interactions and disturbances in sleep disorders.","volume":"31(1)","author":"AN Vgontzas","year":"2002","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1212\/WNL.50.4.1149","article-title":"In vivo and in vitro immune variables in patients with narcolepsy and HLA-DR2 matched controls.","volume":"50(4)","author":"D Hinze-Selch","year":"1998","journal-title":"Neurology"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.bbi.2003.11.002","article-title":"Exploring the cytokine and endocrine involvement in narcolepsy.","volume":"18(4)","author":"ML Okun","year":"2004","journal-title":"Brain Behav Immun"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1001\/archinte.166.16.1739","article-title":"Plasma levels of tumor necrosis factor alpha and soluble tumor necrosis factor receptors in patients with narcolepsy.","volume":"166(16)","author":"H Himmerich","year":"2006","journal-title":"Arch Intern Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1034\/j.1399-0039.2000.560508.x","article-title":"Significant association of the tumor necrosis factor receptor 2 (TNFR2) gene with human narcolepsy.","volume":"56(5)","author":"H Hohjoh","year":"2000","journal-title":"Tissue Antigens,"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1034\/j.1399-0039.1999.540204.x","article-title":"Significant association of a single nucleotide polymorphism in the tumor necrosis factor-alpha (TNF-alpha) gene promoter with human narcolepsy.","volume":"54(2)","author":"H Hohjoh","year":"1999","journal-title":"Tissue Antigens"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1034\/j.1399-0039.2003.00068.x","article-title":"TNFA promoter polymorphisms and narcolepsy.","volume":"61(6)","author":"S Wieczorek","year":"2003","journal-title":"Tissue Antigens"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1126\/science.1097243","article-title":"Visfatin: a protein secreted by visceral fat that mimics the effects of insulin.","volume":"307(5708)","author":"A Fukuhara","year":"2005","journal-title":"Science"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.4049\/jimmunol.178.3.1748","article-title":"Visfatin, an adipocytokine with proinflammatory and immunomodulating properties.","volume":"178","author":"AR Moschen","year":"2007","journal-title":"J Immunol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1210\/en.2003-0580","article-title":"Minireview: The adipocyte\u2013at the crossroads of energy homeostasis, inflammation, and atherosclerosis.","volume":"144","author":"MW Rajala","year":"2003","journal-title":"Endocrinology"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nri1937","article-title":"Adipocytokines: mediators linking adipose tissue, inflammation and immunity.","volume":"6(10)","author":"H Tilg","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1055\/s-2007-985867","article-title":"Visfatin: A Putative Biomarker for Metabolic Syndrome is not Influenced by Pioglitazone or Simvastatin Treatment in Nondiabetic Patients at Cardiovascular Risk-Results from the PIOSTAT Study.","volume":"39","author":"A Pf\u00fctzner","year":"2007","journal-title":"Horm Metab Res"},{"key":"ref26","article-title":"ICSD\u2014International classification of sleep disorders: Diagnostic and coding manual.","author":"MJ Thorpy","year":"1990"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0960-5428(94)00043-N","article-title":"Narcolepsy and immunity.","volume":"5(1)","author":"E Mignot","year":"1995","journal-title":"Adv Neuroimmunol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1055\/s-2007-973075","article-title":"TNF-alpha alters visfatin and adiponectin levels in human fat.","volume":"39(4)","author":"J Hector","year":"2007","journal-title":"Horm Metab Res"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.metabol.2006.07.011","article-title":"Narcolepsy and the hypocretins.","volume":"55","author":"RJ Wurtmann","year":"2006","journal-title":"Metabolism"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1136\/ard.2005.046540","article-title":"Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis.","volume":"64","author":"M Otero","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.2337\/db06-0259","article-title":"Serum visfatin increases with progressive beta-cell deterioration.","volume":"55(10)","author":"A Lopez-Bermejo","year":"2006","journal-title":"Diabetes"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/BF03347412","article-title":"Visfatin\/pre-B-cell colony-enhancing factor: a protein with various suggested functions.","volume":"30(2)","author":"S Pilz","year":"2007","journal-title":"J Endocrinol Invest"},{"key":"ref33","first-page":"505","article-title":"Adipocytokines - novel link between inflammation and vascular function?","volume":"57(4)","author":"TJ Guzik","year":"2006","journal-title":"J Physiol Pharmacol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/archneur.59.10.1553","article-title":"The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias.","volume":"59(10)","author":"E Mignot","year":"2002","journal-title":"Arch Neurol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.2337\/diabetes.54.10.2911","article-title":"Plasma visfatin concentrations and fat depot-specific mRNA expression in humans.","volume":"54(10)","author":"J Berndt","year":"2005","journal-title":"Diabetes"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/sj.jhh.1002114","article-title":"Plasma visfatin levels in young male patients with uncomplicated and newly diagnosed hypertension.","volume":"21(2)","author":"T Dogru","year":"2007","journal-title":"J Hum Hypertens"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.diabres.2006.07.031","article-title":"Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance.","volume":"76(1)","author":"T Dogru","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1210\/jc.2006-1303","article-title":"Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation.","volume":"92(2)","author":"V Varma","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"ref39","first-page":"188","article-title":"Visfatin levels do not change after the oral glucose tolerance test and after a dexamethasone-induced increase in insulin resistance in humans.","volume":"58(3)","author":"M Marcinkowska","year":"2007","journal-title":"Endokrynol Pol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.fertnstert.2006.11.120","article-title":"Increased plasma visfatin concentrations in women with polycystic ovary syndrome.","volume":"88(2)","author":"TF Chan","year":"2007","journal-title":"Fertil Steril"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/sj.mp.4000911","article-title":"MAO-A and COMT polymorphisms and gene effects in narcolepsy.","volume":"6(4)","author":"Y Dauvilliers","year":"2001","journal-title":"Mol Psychiatry."}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0002980","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T03:55:02Z","timestamp":1540266902000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0002980"}},"subtitle":[],"editor":[{"given":"Naomi","family":"Rogers","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2008,8,20]]},"references-count":41,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2008,8,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0002980","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,20]]}}}